002365.SZ
Qianjiang Yongan Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 11.25
+1.44%Oct 29, 2026, 07:49 UTC
Yongan Pharmaceutical reported third-quarter 2026 revenue of 385 million yuan, up 83.53% year over year, and attributable net profit of 71.0212 million yuan, up 446.29%; revenue for the first nine months was 949 million yuan, up 64.38%, and attributable net profit was 114 million yuan, up 348.81%.
Source:Sep 22, 2026, 14:10 UTC
Twelve A-share listed companies including Chuhuan Technology, Yongan Pharmaceutical, Haichen Co., Kejingyuan, Tianyima, Jianan Intelligent, Genvict Technologies, Huasu Holding, MicuRx Pharmaceuticals, Hainan Ruize, North Industries, and China Nuclear Engineering disclosed planned share reductions on September 22.
Source:Sep 22, 2026, 12:24 UTC
Five directors and senior executives of Yongan Pharmaceutical plan to sell a combined 452,900 shares, or 0.1537% of the company's total share capital, via centralized bidding within three months after a 15-trading-day waiting period.
Aug 27, 2026, 07:58 UTC
Yongan Pharmaceutical plans to sign a framework agreement with Zhejiang Shuangzi Intelligent Equipment Co., Ltd. for equipment supply and related services, with a total transaction amount not exceeding 10 million yuan and a one-year validity period.
Source: